clarithromycin has been researched along with zanamivir in 4 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (25.00) | 29.6817 |
2010's | 3 (75.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Lombardo, F; Obach, RS; Waters, NJ | 1 |
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
Ishii, H; Ishimoto, H; Kadota, JI; Mukae, H; Nishida, C; Noguchi, S; Sakamoto, N; Umeki, K; Yamasaki, K; Yatera, K | 1 |
Chan, KH; Hung, IFN; Kao, RYT; Lee, ACY; Li, C; To, KKW; Yuen, KY; Zhang, AJX; Zhang, RR; Zhu, H | 1 |
4 other study(ies) available for clarithromycin and zanamivir
Article | Year |
---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
The additive effect of clarithromycin on influenza A infection in the elderly patients and patients with comorbid diseases.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antiviral Agents; Clarithromycin; Cohort Studies; Comorbidity; Drug Therapy, Combination; Enzyme Inhibitors; Female; Humans; Influenza A virus; Influenza, Human; Male; Middle Aged; Neuraminidase; Oseltamivir; Phosphorous Acids; Pneumonia; Prospective Studies; Treatment Outcome; Zanamivir | 2017 |
Triple combination of FDA-approved drugs including flufenamic acid, clarithromycin and zanamivir improves survival of severe influenza in mice.
Topics: Animals; Antiviral Agents; Clarithromycin; Drug Approval; Drug Evaluation, Preclinical; Drug Therapy, Combination; Female; Flufenamic Acid; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Interleukin-1beta; Lung; Mice; Mice, Inbred BALB C; Tumor Necrosis Factor-alpha; United States; United States Food and Drug Administration; Zanamivir | 2018 |